Browsing Tag
immuno-oncology
30 posts
First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer
Find out how Adagene’s Muzastotug and KEYTRUDA combination could redefine immunotherapy for microsatellite stable colorectal cancer.
How Purple Biotech’s CAPTN-3 platform achieved a tri-specific antibody manufacturing milestone with IM1240
Find out how Purple Biotech’s manufacturing milestone for IM1240 is validating the CAPTN-3 platform and transforming tri-specific antibody development.
RNAZ stock surges as TransCode Therapeutics buys Polynoma and wins $25m CK Life Sciences funding for metastatic cancer pipeline
Find out how TransCode Therapeutics’ $25M CK Life Sciences funding and Polynoma buyout could redefine RNAZ’s role in cancer immunotherapy.
HanchorBio and Henlius sign $202m licensing deal for HCB101 to expand immuno-oncology access across Asia and MENA
HanchorBio Inc. (7827.TWO), a clinical-stage immunotherapy innovator, has entered a major licensing agreement with Shanghai Henlius Biotech Inc.…
Dr Reddy’s launches toripalimab in India as first immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. announced a significant milestone in its oncology portfolio with the launch of Toripalimab in…
Xencor stock skyrockets 26% overnight after breakthrough in cancer research
Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by…
Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a…
GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab)…
Affimed N.V. reports promising results from AFM24-102 trial in NSCLC
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study,…
FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate…